What's Happening?
INOVIO and Akeso have announced a clinical collaboration to evaluate a novel combination therapy for glioblastoma (GBM), the most aggressive form of brain cancer. The collaboration will test INOVIO's DNA immunotherapy candidate, INO-5412, in combination with
Akeso's bispecific antibody, cadonilimab, as part of the INSIGhT trial. This Phase 2 adaptive platform trial, sponsored by the Dana-Farber Cancer Institute, aims to find new treatments for GBM. The trial will begin dosing in the second half of 2026. INO-5412 combines INO-5401 and INO-9012, which have shown promising results in eliciting immune responses and potentially enhancing survival in GBM patients. Cadonilimab, approved in China for several cancer indications, offers dual checkpoint inhibition, which may improve treatment outcomes.
Why It's Important?
This collaboration is significant as it addresses the urgent need for effective treatments for glioblastoma, a cancer with a poor prognosis and limited therapeutic options. The combination of INO-5412 and cadonilimab could potentially enhance immune responses and improve survival rates for GBM patients. The trial's success could lead to new standards in cancer immunotherapy, offering hope to patients with this challenging disease. The partnership also highlights the growing trend of combining innovative therapies to tackle complex cancers, potentially setting a precedent for future collaborations in the biotech industry.
What's Next?
The INSIGhT trial will proceed with dosing expected to start in late 2026. The trial will assess the safety and efficacy of the combination therapy in patients with newly diagnosed GBM. If successful, this could lead to further clinical trials and eventual regulatory approval, expanding treatment options for GBM patients. Stakeholders, including healthcare providers and patients, will be closely monitoring the trial's progress, as positive results could significantly impact treatment protocols and patient outcomes.
